Impact of clinical pharmacist intervention on blood glucose control and perinatal outcomes in gestational diabetes mellitus through a diabetes management system

Background: Very few studies have assessed the role of a clinical pharmacist in women with gestational diabetes mellitus (GDM). To improve pharmaceutical care, we explored a method to improve the control of blood glucose and perinatal outcomes in females with GDM through the application of a diabete...

Full description

Saved in:
Bibliographic Details
Main Authors: C. Ji (Author), L.J. Sun (Author), L.T. Li (Author), J. Ma (Author), W.H. Ge (Author), X. Zhao (Author)
Format: Book
Published: IMR Press, 2020-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_7c476040bc5a4d3f9baade12fefcf33f
042 |a dc 
100 1 0 |a C. Ji  |e author 
700 1 0 |a L.J. Sun  |e author 
700 1 0 |a L.T. Li  |e author 
700 1 0 |a J. Ma  |e author 
700 1 0 |a W.H. Ge  |e author 
700 1 0 |a X. Zhao  |e author 
245 0 0 |a Impact of clinical pharmacist intervention on blood glucose control and perinatal outcomes in gestational diabetes mellitus through a diabetes management system 
260 |b IMR Press,   |c 2020-10-01T00:00:00Z. 
500 |a 0390-6663 
500 |a 10.31083/j.ceog.2020.05.2212 
520 |a Background: Very few studies have assessed the role of a clinical pharmacist in women with gestational diabetes mellitus (GDM). To improve pharmaceutical care, we explored a method to improve the control of blood glucose and perinatal outcomes in females with GDM through the application of a diabetes management system. Methods: A randomized controlled trial was conducted from October 2017 to October 2018 for 200 outpatients with GDM. In the study, a diabetes management system with pharmaceutical care was used for the intervention group. The clinical outcomes of all patients were recorded at the end of delivery. Results: From one sample of 200 patients, 169 finished the research. Compared with the control group, patients in the intervention group manifested greater reductions in fasting plasma glucose (5.22 ± 0.37 vs. 6.05 ± 1.06 mmol/L; P = 0.018), 2 h postprandial plasma glucose (6.66 ± 0.57 vs. 9.69 ± 1.58 mmol/L; P = 0.00), and glycated hemoglobin A1c corrected values (1.02 ± 0.12 vs. 1.16 ± 0.22; P = 0.023). Moreover, the rate of polyhydramnios was significantly lower in the intervention group than in the control group (0% vs. 10.59%; P = 0.003) as well as significantly fewer macrosomia in the intervention group (7.14% vs. 18.82%; P = 0.038). Conclusions: Using a diabetes management system, clinical pharmacists can improve the control of blood glucose and perinatal results in GDM females. With a diabetes management system, the comprehensive management of GDM is a new model for pharmaceutical care in the future. 
546 |a EN 
690 |a clinical pharmacist 
690 |a diabetes management system 
690 |a gestational diabetes mellitus 
690 |a blood glucose control 
690 |a perinatal outcome 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n Clinical and Experimental Obstetrics & Gynecology, Vol 47, Iss 5, Pp 645-652 (2020) 
787 0 |n https://www.imrpress.com/journal/CEOG/47/5/10.31083/j.ceog.2020.05.2212 
787 0 |n https://doaj.org/toc/0390-6663 
856 4 1 |u https://doaj.org/article/7c476040bc5a4d3f9baade12fefcf33f  |z Connect to this object online.